Abstract
Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
| Original language | English |
|---|---|
| Article number | 518 |
| Journal | Cancers |
| Volume | 14 |
| Issue number | 3 |
| ISSN | 2072-6694 |
| DOIs | |
| Publication status | Published - 01.02.2022 |
Funding
Conflicts of Interest: AG speaker’s honoraria from Bristol-Myers Squibb, MSD Sharp and Dohme and Roche; intermittent advisory board relationships with Amgen, Bristol-Myers Squibb, Novartis, MSD Sharp and Dohme, Pierre Fabre Pharmaceuticals, Pfizer, Roche and Sanofi Genzyme; travel and congress fee support from Bristol-Myers Squibb, MSD Sharp and Dohme, Novartis, Pierre Fabre Pharmaceuticals and Roche. Clinical studies: Amgen, Array, Bristol-Myers Squibb, GSK, Novartis, Merck, MSD Sharp and Dohme, Pfizer and Roche. BST declares advisory board honoraria from Io-vance. CL: Advisory board: MSD, BMS, Merck, Roche, Pierre Fabre, Novartis, Biontech, Sun Pharma, Kyowa Kirin, Almiral Hermal, Sanofi Speekers fee: MSD, BMS, Merck, Roche, Pierre Fabre, Novartis, Biontech, Sun Pharma, Kyowa Kirin, Almiral Hermal, Sanofi Travel reimbursement: MSD, BMS, Merck, Roche, Pierre Fabre, Novartis, Biontech, Sun Pharma, Kyowa Kirin, Almiral Hermal, Sanofi. CP received honoraria (speaker honoraria or honoraria as a consultant) and travel support from: Novartis, BMS, Roche, Merck Serono, MSD, Celgene, AbbVie, SUNPHARMA, UCB, Allergy Therapeutics, Pierre Fabre, Kyowa Kirin, and LEO. ED has no reports on research support (to institution) or honoraria for lectures (personally). FM has received travel support or/and speaker’s fees or/and advisor’s honoraria from Novartis, Roche, BMS, MSD, and Pierre Fabre and research funding from Novartis and Roche. FZ declares speakers and advisory board honoraria and/or travel support from BMS, MSD, Roche, Novartis, Pierre-Fabre, and Sanofi-Aventis outside the submitted work. JCH declares research support from BMS, advisory board honoraria from Pierre Fabre, Sanofi, Sun-pharma and MSD, speakers honoraria from BMS, MSD, Novartis, Roche, Sanofi and Almirall, and travel support from Pierre Fabre. JU is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, Sanofi outside the submitted work. KK serves as consultant to Roche, BMS, MSD and received travel grants and speaker fees from Roche, BMS, MSD, Novartis, Amgen. KMT received speaker or consultant honoraria and travel support from Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novartis, Pierre Fabre, Sun Pharma, Sanofi Genzyme, LEO, Galderma, Almirall, La Roche-Posay, and Candela. MS reports receiving honoraria and participation in advisory boards of Bristol-Myers Squibb, Novartis, MSD, Roche, Pierre Fabre, Kyowa Kirin, Immuno-core, and Sanofi-Genzyme. MS received travel accommodation and expenses by Novartis, Pierre Fabre, and Sun Pharma. PT: BMS, Novartis, MSD, Pierre-Fabre, CureVac, Roche, Kyowa Kirin, Bio-frontera, Invited Speaker, Personal BMS, Novartis, Pierre-Fabre, Merck Serono, Sanofi, Roche, Kyowa Kirin, Advisory Board, Personal BMS, Pierre-Fabre, Other, Personal, Travel support. RG Research support: Pfizer, Johnson&Johnson, Novartis, Amgen, MerckSerono, SUN Pharma, Sanofi. Honoraria for lectures: Roche Pharma, Bristol-Myers Squibb, Novartis, MSD, Almirall-Hermal, Amgen, Merck-Serono, SUN, Pierre-Fabre, Sanofi, SUN Pharma, Bayer Honoraria for advisory boards: Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Almirall-Hermal, Amgen, Pierre-Fa-bre, Merck-Serono, 4SC, Immunocore, SUN Pharma, Sanofi, Pfizer. SU declares research support from Bristol Myers Squibb and Merck Serono; speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp and Dohme, Merck Serono, Novartis and Roche, and travel support from Bristol Myers Squibb, Merck Sharp and Dohme, and Pierre Fabre. UL reports on advisory boards and Speakers Fees: MSD, Novartis, Sun Pharma, Almirall Hermal, Sanofi, Roche, and Research foundation MSD, Travel and congress fee support: Sun Pharma. Funding: M.V.H. was supported by the clinician scientist program awarded by the German Society of Dermatology (DDG) and the Arbeitsgemeinschaft Dermatologische Forschung (ADF).
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
- Research Area: Luebeck Integrated Oncology Network (LION)
- Centers: University Cancer Center Schleswig-Holstein (UCCSH)
DFG Research Classification Scheme
- 2.22-19 Dermatology
- 2.21-05 Immunology
- 2.22-14 Hematology, Oncology
